Systemic bevacizumab (Avastin®) Therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-study.

Katharina E Schmid-Kubista (1) , Ilse Krebs (1) , Birgit Gruenberger (2) , Johann Schueller (2) , Susanne Binder (1)

1 Department of Ophthalmology, Rudolf Foundation Clinic
2 Department of Internal Medicine, Oncology, Rudolf Foundation Clinic

Double-blinded, randomised, prospective, pilot-study to determine the effect of systemic bevacizumab therapy.

Mots clés: Macula; Vision; Neovascularisation; Degeneration; Treatment Medical; Age-Related Macular Degeneration; Bevacizumab; Placebo; Systemic Therapy

Katharina E Schmid-Kubista, Ilse Krebs, Birgit Gruenberger, Johann Schueller, Susanne Binder. Systemic bevacizumab (Avastin®) Therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-study.. British Journal of Ophthalmology, 2009, 93 (7), pp.914-n/a. ⟨10.1136/bjo.2008.144410⟩. ⟨hal-00477810⟩